UBS Maintains Buy on Chemed, Raises Price Target to $675
UBS analyst A.J. Rice maintains Chemed (NYSE:CHE) with a Buy and raises the price target from $650 to $675.
Share
Why It Matters
An expert investor watcher thinks Chemed is a good company to own. They think the stock could be worth a bit more money soon.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.